Menlo Park, CA — Encrantz Staffan, a director and major shareholder Vision Sciences Inc. (NASDAQ: ) recently disclosed the sale of 551,802 shares of the company’s common stock. The transaction, which was completed on November 21, 2024, was executed at a price of $3.73 per share, for a total value of approximately $2.06 million.
Following the sale, Encrantz retained ownership of 632,456 shares through indirect holdings. The shares sold were previously held and transferred to the 1997 Staffan Ankrantz and Margarita Ankrantz Revocable Trust. Allegro (WA:) Investment Fund, LP, where Encrantz serves as President of the Investment Manager.
In a parallel transaction, Encrantz acquired an equal number of shares, 551,802, also valued at $2.06 million through Allegro Investment Fund, leaving no net change to its total stake. The acquisition was executed at the same price of $3.73 per share.
Encrantz’s transaction did not change his total direct and indirect holdings, which now stand at 1,029,516 shares, including restricted stock units subject to vesting.
In other recent news, Sight Sciences, Inc. reported a slight year-over-year increase in revenue in its third-quarter earnings, though the results fell short of expectations. The company’s revenue rose 1% to $20.2 million, with surgical glaucoma revenue accounting for $18.6 million of that amount. Despite the setbacks, Sight Sciences is optimistic about growth in the surgical glaucoma and dry eye segments in 2025.
The company is contesting the 2025 Medicare payment rule, which did not grant OMNI’s procedure device status. Sight Sciences is also focusing on enhancing its sales performance and strategic positioning in response to commercial challenges. These developments are part of the company’s long-term growth strategy, particularly in the surgical glaucoma segment.
The company has forecast full-year revenue between $81 million and $83 million. Operating expenses for 2024 have been adjusted from $104 million to $106 million. Sight Sciences has appointed Dr. MK Raheja as Executive Vice President of Research and Development, further signaling its commitment to advancing its surgical glaucoma pipeline.
InvestingPro Insights
Sight Sciences, Inc. (NASDAQ:SGHT) has been experiencing significant volatility in its stock price, as highlighted by recent insider trading. This volatility is confirmed by Investing Pro Tip which shows that SGHT’s stock price movement is indeed quite volatile. The company’s market capitalization currently stands at $190.84 million, reflecting its position as a small player in the medical devices sector.
Despite the recent insider selling at $3.73 per share, it’s worth noting that SGHT’s stock has shown a strong performance over the past year, with a 1-year total price return of 50.4%. This is consistent with another InvestingPro tip that suggests higher returns over the past year. However, recent performance has been challenging, with a 3-month price total return of -40.51%, indicating significant short-term pressure on the stock.
Financially, Site Sciences presents a mixed picture. The company has more cash than debt on its balance sheet, which is a positive sign for financial stability. However, it is important to note that SGHT is not currently profitable, with negative operating income of $49.71 million in the trailing twelve months as of Q3 2024. This financial position is reflected in the company’s price-to-earnings (P/E) ratio. of -3.74, suggesting that investors are pricing in future growth potential rather than current earnings.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 10 more tips available for Sight Sciences. These propositions can provide valuable context for a more detailed understanding of a company’s financial health and market position.
This article was produced in collaboration with AI and was reviewed by an editor. See our T&C for more information.
